MOLECULAR IMAGING OF DEMENTIA - THE FUTURE IS HERE

FINAL PROGRAMME
The European Association of Nuclear Medicine (EANM), the world-leading society for nuclear medicine, molecular imaging and theranostics, is pleased to continue the EANM Focus Meeting – an annual conference in a new format that will take place in the first months of each year. It will supplement the very successful EANM Annual Congress in October and the educational events organised by EANM/ESMIT.
Molecular Imaging of Dementia – The Future is Here

For the EANM Focus Meeting we are welcoming a multidisciplinary group of experts and opinion leaders from all over the world.

EANM is very pleased that a large faculty of neurologists, radiologists, geriatricians, psychiatrists, imagers, clinical and basic scientists and patient-advocates has agreed to lecture and participate in the discussions. The aim of the meeting is to provide an in-depth overview and critical assessment of the latest development and future directions in the management of dementia, with a focus on the role of neuroimaging in general and nuclear medicine in particular. The goal is to arrive at a multidisciplinary consensus on the current state of the art and to make expert recommendations how to advance the field towards establishing clinical impact.

We hope you will enjoy the meeting in the beautiful city of Cannes.

With best personal regards,
Wim J.G. Oyen and Gaël Chételat
## OVERALL PROGRAMME

### Thursday, January 31, 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30</td>
<td>Registration Desk Open</td>
</tr>
<tr>
<td>08:30 – 09:00</td>
<td>Opening</td>
</tr>
<tr>
<td>09:00 – 10:35</td>
<td>Track 1 – First Part</td>
</tr>
<tr>
<td>10:35 – 11:00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11:00 – 13:00</td>
<td>Track 1 – Second Part</td>
</tr>
<tr>
<td>13:00 – 14:00</td>
<td>Lunch Break</td>
</tr>
<tr>
<td>14:00 – 15:25</td>
<td>Track 2 – First Part</td>
</tr>
<tr>
<td>15:25 – 16:00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>16:00 – 18:00</td>
<td>Track 2 – Second Part</td>
</tr>
<tr>
<td>18:00 – 19:00</td>
<td>Welcome Reception (at conference venue)</td>
</tr>
</tbody>
</table>

### Friday, February 1, 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>Registration Desk Open</td>
</tr>
<tr>
<td>09:00 – 10:40</td>
<td>Track 3 – First Part</td>
</tr>
<tr>
<td>10:40 – 11:00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11:00 – 13:00</td>
<td>Track 3 – Second Part</td>
</tr>
<tr>
<td>13:00 – 14:00</td>
<td>Lunch Break</td>
</tr>
<tr>
<td>14:00 – 15:35</td>
<td>Track 4 – First Part</td>
</tr>
<tr>
<td>15:35 – 16:00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>16:00 – 18:00</td>
<td>Track 4 – Second Part</td>
</tr>
<tr>
<td>19:30</td>
<td>Conference Dinner (at Restaurant Beefhouse)</td>
</tr>
</tbody>
</table>

### Saturday, February 2, 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>Registration Desk Open</td>
</tr>
<tr>
<td>09:00 – 10:35</td>
<td>Track 5 – First Part</td>
</tr>
<tr>
<td>10:35 – 11:00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11:00 – 13:00</td>
<td>Track 5 – Second Part and Closing</td>
</tr>
<tr>
<td>13:00 – 14:00</td>
<td>Farewell Drink (at conference venue)</td>
</tr>
</tbody>
</table>
EUROPEAN NUCLEAR MEDICINE GUIDE

Comprehensive yet concise!
The manual from and for the Nuclear Medicine Community.

http://nucmed-guide.app
Thursday, January 31, 2019 | 09:00 – 13:00

PET as Part of the Biomarker Toolbox for Early Clinical Diagnosis of Alzheimer Disease (AD)

Chairpersons: J. Arbizu, V. Garibotto, P. Scheltens, S. Minoshima

09:00 – 09:20 Unmet Need for Early Diagnosis of Prodromal AD
B. Dubois

09:25 – 09:45 Contribution of MRI for Early Diagnosis of AD
G. Frisoni

09:50 – 10:10 Contribution of CSF for Early Diagnosis of AD
H. Zetterberg

10:15 – 10:35 Contribution of PET for Early Diagnosis of AD
S. Minoshima

11:00 – 11:10 Controversy: Early Diagnosis of AD – PET in the Initial Work-Up
J. Arbizu

11:10 – 11:35 Controversy: In Favour
F. Nobili

11:40 – 12:05 Controversy: Against
P. Scheltens

12:05 – 12:15 Questions & Answers

12:15 – 13:00 Consensus on Imaging for Early Diagnosis of AD
S. Minoshima, J. Arbizu, V. Garibotto
Thursday, January 31, 2019 | 14:00 – 18:00

Molecular Imaging in the Differential Diagnosis of Dementia
Chairpersons: S. Morbelli, J. Arbizu

14:00 – 14:25  Contribution of MRI
F. Agosta

14:30 – 14:55  Unmet Clinical Needs and Contribution of PET in Frontotemporal Lobar Degeneration
G. Rabinovici

15:00 – 15:25  Unmet Clinical Needs and Contribution of Molecular Imaging in Parkinsonian Syndromes
D. Brooks

16:00 – 16:10  Controversy: FDG-First versus Amyloid-First for Differential Dementia Diagnosis?
J. Arbizu

16:15 – 16:35  Controversy: FDG PET-First
D. Perani

16:40 – 17:00  Controversy: Amyloid PET-First
Q. Sabri

17:00 – 17:10  Questions & Answers

17:10 – 18:00  Consensus on Molecular Imaging for Differential Dementia Diagnosis
J. Arbizu, S. Morbelli
Friday, February 1, 2019 | 09:00 – 13:00

Clinical Acceptance of Amyloid Imaging
Chairpersons: V. Garibotto, A. Drzezga

ROUND TABLE: Evidence for a Routine Use of Amyloid Markers
09:00 – 09:30
Introduction: The Current Status of Amyloid Markers (PET and CSF) Reimbursement and the Point of View of the Payers and the Industry in the IMI-2 Initiative
G. Frisoni

09:35 – 09:50
Clinical Use of “Freely Accessible” Amyloid Markers – The Example of Sweden
A. Nordberg

09:55 – 10:15
The Point of View of the Scientific Community
S. Landau

10:20 – 10:40
The Point of View of the Patients and the Families
M.C. Carrillo

11:00 – 11:20
Ongoing Studies to Provide Answers: AMYPAD and Other European Initiatives
F. Barkhof

11:25 – 11:45
Ongoing Studies to Provide Answers: IDEAS and Other Collaborative Efforts Worldwide
G. Rabinovici

DISCUSSION AND CONSENSUS
11:50 – 12:30
Consensus on Clinical Use of Amyloid Markers
A. Drzezga

12:30 – 13:00
Consensus on Research Priorities
V. Garibotto
The Use of PET in Dementia Research

Chairpersons: H. Barthel, G. Chételat, A. Drzezga

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 – 14:20</td>
<td>Impact of Brain Connectivity and Reserve in Dementia</td>
</tr>
<tr>
<td></td>
<td>G. Chételat</td>
</tr>
<tr>
<td></td>
<td><strong>ROUND TABLE: The Complementarity of Neuroimaging</strong></td>
</tr>
<tr>
<td></td>
<td>Techniques in Clinical Trials i) to Enrich Target Populations and</td>
</tr>
<tr>
<td></td>
<td>ii) to Monitor Drug Effects</td>
</tr>
<tr>
<td>14:25 – 14:45</td>
<td>FDG-PET Imaging</td>
</tr>
<tr>
<td></td>
<td>K. Herholz</td>
</tr>
<tr>
<td>14:50 – 15:10</td>
<td>MR Imaging</td>
</tr>
<tr>
<td></td>
<td>P. Scheltens</td>
</tr>
<tr>
<td>15:15 – 15:35</td>
<td>Amyloid and Tau-PET Imaging</td>
</tr>
<tr>
<td></td>
<td>V. Villemagne</td>
</tr>
<tr>
<td>16:00 – 16:10</td>
<td>Controversy: Guidelines for Research Criteria in Preclinical AD:</td>
</tr>
<tr>
<td></td>
<td>Should Amyloid be Considered as the Lead Biomarker in the Hierarchy?</td>
</tr>
<tr>
<td></td>
<td>A. Drzezga</td>
</tr>
<tr>
<td>16:15 – 16:35</td>
<td>Controversy: In Favour</td>
</tr>
<tr>
<td></td>
<td>C. Jack</td>
</tr>
<tr>
<td>16:40 – 17:00</td>
<td>Controversy: Against</td>
</tr>
<tr>
<td></td>
<td>A. Fjell</td>
</tr>
<tr>
<td>17:00 – 17:35</td>
<td>Consensus on Hierarchy of Biomarkers in Preclinical AD</td>
</tr>
<tr>
<td></td>
<td>A. Drzezga</td>
</tr>
<tr>
<td>17:40 – 18:00</td>
<td>Do We Need Multimodal Imaging?</td>
</tr>
<tr>
<td></td>
<td>A. Drzezga</td>
</tr>
</tbody>
</table>
New Developments and Methodology

Chairpersons: I. Law, E. van de Giessen, H. Barthel

09:00 – 09:20 Imaging of Neuroinflammation in Neurodegeneration – What does it Add to Our Understanding? D. J. Brooks

09:25 – 09:45 Principles of Absolute PET Quantification for Monitoring Longitudinal Treatment Response? A. Lammertsma

09:50 – 10:10 Amyloid and Tau Imaging: Centiloid, Centaur, and Clinical Use V. Villemagne

10:15 – 10:35 PET-Tau Imaging for Early and Differential Diagnosis of AD O. Hansson

11:00 – 11:20 Standards for In-Vitro Validation of PET Tracers in Neurodegeneration A. Nordberg

11:25 – 11:55 Hybrid PET/MRI: Has it Developed the Dementia Field? H. Barthel

12:00 – 12:20 Issues in Quantification for Neurological PET Studies B. Hutton

12:25 – 13:00 Discussion: What else do We Need for Progress? (New Tracers, Artificial Intelligence, etc.) I. Law, E. van de Giessen
PANELLISTS

We kindly thank our panellists for their valuable support.
PANELISTS

INTERNATIONAL CONFERENCE ON "MOLECULAR IMAGING OF DEMENTIA - THE FUTURE IS HERE"
PANELISTS
INTERNATIONAL CONFERENCE ON "MOLECULAR IMAGING OF DEMENTIA - THE FUTURE IS HERE"
Federica Agosta took her Post-Degree Graduation in Neurology in 2008 and PhD in Experimental Neurology in 2012. Currently, she is an Assistant Professor of Neurology at the Vita-Salute San Raffaele University and Group Leader at the Division of Neuroscience, Ospedale San Raffaele (OSR), Milan, where she conducts research in patients with neurodegenerative conditions. She has a broad background in clinical neurology and neuroimaging, with specific training and expertise in MRI and neurodegenerative diseases. During her PhD at Vita-Salute San Raffaele University (2009-2012), she dealt with several aspects of pathophysiology of neurodegenerative diseases using MR techniques, with particular interest in young onset dementia and ALS. Her research has led to the publication of over 200 Pubmed-referenced papers. She is Section Editor of the NeuroImage: Clinical journal. In 2016, she has been awarded an ERC Starting Grant.

Dr. Javier Arbizu is currently Professor of Radiology and Radiobiology, Department of Nuclear Medicine, University of Navarra, and Director of Neuroimaging and Radionuclide Therapy Unit, Department of Nuclear Medicine, University of Navarra Clinic. Pamplona, SPAIN

He completed his nuclear medicine residency at University of Navarra Clinic, Spain; research residency at Mount Sinai Medical Center, New York, US; and research fellowship at UPMC, University of Pittsburgh, US. Dr. Arbizu participates and leads different projects in the field of Alzheimer disease, parkinsonian syndromes and brain tumors. He is member of the Editorial Board of the Eur J Nucl Med Mol Imaging, and vice-chairman of the Neuroimaging Committee of the EANM participating actively with clinical scientific societies to develop new uses and guidelines of molecular neuroimaging. He is also member of the SNMMI, involved in the Board of Directors of the Brain Imaging Council.
3  Frederik Barkhof  
Amsterdam, Netherlands

Frederik Barkhof received his MD from VU University, Amsterdam (NL) in 1988 and defended his PhD thesis in 1992, for which he received the Philips Prize for Radiology (1992) and the Lucien Appel Prize for Neuroradiology (1994). Since 2001 he serves as a full Professor in Neuroradiology at the department of Radiology & Nuclear Medicine at VUmc. In 2015 he was appointed as full Professor of Neuroradiology at institutes of Biomedical Engineering and Neurology at UCL in London (UK) to translate novel imaging techniques. In 2018 he received the John Dystel prize by the US National MS Society and the American Academy of Neurology outstanding contributions to research in MS.

Prof. Barkhof was the chairman of the Dutch Society of Neuroradiology and the MAGNIMS study group for many years. He is leading the Queen Square MS Centre Trial Unit and serves on the Editorial boards of Radiology, Brain, Multiple Sclerosis Journal, Neuroradiology and Neurology.

4  Henryk Barthel  
Leipzig, Germany

Henryk Barthel, MD, PhD, is Professor and Assistant Medical Director of the Department of Nuclear Medicine of the University Hospital Leipzig (Germany). He underwent training in Nuclear Medicine in Heidelberg and Leipzig. From 2000 to 2003 he worked as a Research Fellow at the Imperial College Hammersmith Hospital in London (UK). Prof. Barthel’s current preclinical and clinical research activities focus on new PET imaging techniques to improve diagnosis and treatment in Alzheimer’s disease and stroke, as well as on hybrid brain PET/MR imaging. To support the general progress of nuclear brain imaging, he served as President of the SNMMI Brain Imaging Council, and is a Member of the EANM Neuroimaging Committee. He is Associate Editor for The Journal of Nuclear Medicine.

3  Ongoing Studies to Provide Answers – AMYPAD and Other European Initiatives

4  Hybrid PET/MRI: Has it Developed the Dementia Field?
5  David BROOKS
Newcastle, UK

David J. Brooks MD DSc FRCP(UK) FMed Sci (UK) is Professor of Clinical PET Research at Newcastle University and Professor of Neurology at Aarhus University, Denmark. He is Chairman of the European Research Council Advanced Neuroscience Panel and is on the Grant Awards Board of Alzheimer Research UK, the Biomedical Research Advisory Panel of Alzheimer UK, and was on the Scientific Advisory Boards of Parkinson’s UK, and the German Dementia and the Parkinson Kompetenz Networks. He is an Associate Editor of Brain and Molecular Imaging and Biology and is on the Editorial Board of Annals of Neurology. He is a Fellow of the Academy of Medical Science, UK and his research involves the use of PET and MRI to study the pathology and progression of Alzheimer’s and Parkinson’s diseases. He has been a recipient of the Ramon Y Cajal award from the Spanish Medical Academy, the Danish Alzheimer Foundation Prize, and the Kuhl-Lassen award (Society of Nuclear Medicine).

6  Maria C. CARRILLO
Chicago, USA

Maria C. Carrillo, Ph.D., is Chief Science Officer at the Alzheimer’s Association. Dr. Carrillo has oversight of the Association’s grant-making process and communication of scientific findings within and outside of the organization. Dr. Carrillo was on the Advisory Committee for the World Health Organization Dementia Setting Priorities & Portfolio Analysis. She is a member of the National Advisory Council on Aging, which advises the Secretary of the U.S. Department of Health and Human Services, and the Directors of the U.S National Institutes of Health and National Institute on Aging. Dr. Carrillo received her Ph.D. from Northwestern University’s Institute for Neuroscience in 1996. She completed a postdoctoral fellowship in the Division of Neurological Sciences at Rush University Medical Center in Chicago, where she later took a position as an assistant professor.
Gaël Chételat (PhD, HDR) is Director of Research at Inserm. She is responsible of a research team named «Multimodal Neuroimaging and Lifestyle in Ageing and Dementia». She has published more than 150 articles on neuroimaging in ageing and dementia. Her work is devoted to the understanding of the mechanisms underlying ageing and dementia processes and the lifestyle factors that could prevent or delay age-associated disorders. The specificity of her team is to conduct studies combining complementary neuroimaging modalities, including structural and functional MRI with PET using different radiotracers, and to develop innovative multimodal neuroimaging approaches to disentangle complex mechanisms of diseases or cognitive processes. Her research team is also interested in promoting healthy ageing and wellbeing through non-pharmaceutical interventions. In particular, Gaël Chételat is coordinating an H2020 European grant (www.silversantestudy.eu, PHC22, 2015-2020) that will investigate the impact of English learning and meditation training on mental health and well-being in ageing populations.

Alexander Drzezga is Head of the Department of Nuclear Medicine at the University Hospital of Cologne and full Professor at the University of Cologne. He received his MD degree from Technische Universität München (TUM), Munich, Germany and is a board certified nuclear medicine physician since 2003. Since 2005 he has been Assistant Professor for Nuclear Medicine of the Department of Nuclear Medicine at TUM. In 2009, he joined the Martinos Center for Biological Imaging, Harvard University, Boston, USA as a Visiting Professor. In 2011, he was awarded a “Heisenberg-Professorship” for Multimodal Imaging at TUM, Munich, Germany. In October 2012, he accepted a position as Professor and Chair of Nuclear Medicine at the University of Cologne. His research focuses on multimodal neuroimaging (PET/CT, MRI, fMRI, PET/MR) in aging and neurodegeneration, on development and evaluation of novel tracers/radiopharmaceuticals, on molecular/multimodal imaging for therapy monitoring in oncology and personal...
PANELLISTS

9  Bruno DUBOIS
   Paris, France

Bruno Dubois is Professor of Neurology at the University Salpêtrière Hospital in Paris, University Pierre & Marie Curie. He is Director of the "Institute for Memory and Alzheimer Disease" (IM2A) and of the Research INSERM Unit on "Cognition and Neuroimaging in Brain Diseases" at the ICM (Institut du Cerveau et de la Moelle Epinière) at the Salpêtrière Hospital.

He has published more than 550 peer-reviewed articles on anatomical and biochemical studies on the central cholinergic systems in rodents and humans, on cognitive neuropharmacology, on neuropsychology in patients with dementia, with special reference to memory, executive functions and frontal lobe behaviors and on biomarkers in neurodegenerative disorders.

Bruno Dubois is a member of the Académie Nationale de Médecine. He is "Chevalier de la Légion d'honneur", and President of the French Society of Neurology.

10  Anders Martin FJELL
    Oslo, Norway

I am working as a professor of cognitive psychology at the Center for Lifespan Changes in Brain and Cognition, University of Oslo, Norway. My research focus is to contribute to understand what happens to the brain and cognitive functions through life, and what we can do about it. A major principle of our research is that most changes in the brain are continuous through life, so that early influences may have lifelong impacts. Consequently, we may get a better understanding of neurocognitive aging by also looking at development. We study large samples of cognitively healthy participants, but also groups with biomedical risks and patients like Alzheimer’s Disease. A special interest is development and aging of episodic memory.
11  **Giovanni FRISONI**  
Geneva, Switzerland

Clinical neurologist, Full Professor of Clinical Neuroscience at the University of Geneva, Switzerland, and Head of the Memory Clinic of the Geneva University Hospital. Former Scientific Director at the National Alzheimer’s Centre in Brescia, Italy, leads a team of 25 imaging scientists in Italy and 10 scientists in Geneva. Author of over 500 scientific papers listed in PubMed, imaging editor for Neurobiology of Aging, and founding editorial board member of The Lancet Neurology. Has led national and international projects funded by the European Commission, IMI, the Alzheimer’s Association, Italian and Swiss Ministry of Health, and industry. Over the years, he has attracted about 30M euros in competitive research funds. Chairman of Alzheimer’s Imaging Consortium at International Conference on Alzheimer’s Disease in 2010 and 2011. Honorary member of the Austrian Neurological Society and of the French Society of Neurology, he has received the 2016 Investigator Award Winner of EAN.

**TRACK 1**  
Contribution of MRI for Early Diagnosis of AD

**TRACK 3**  
Introduction: The Current Status of Amyloid Markers (PET and CSF) Reimbursement and the Point of View of the Payers and the Industry in the IMI-2 Initiative

12  **Valentina GARIBOTTO**  
Geneva, Switzerland

Dr. Valentina Garibotto is senior physician and senior lecturer at the Geneva University and Geneva University Hospital. Her research group works on molecular imaging of neurodegenerative diseases, with a specific interest in causative and protecting factors and novel therapeutic approaches (https://www.unige.ch/medecine/radio/en/groupes-de-recherche/984garibotto/). Her research projects are mainly supported by the Swiss National Science Foundation, the Velux Stiftung and the Aetas foundation. She is Secretary of the Neuroimaging Committee of the European Association of Nuclear Medicine and actively involved in a number of European initiatives fostering molecular imaging of cognitive disturbances, such as the European Alzheimer Disease Consortium PET, the European-Dementia with Lewy Body study group and the AMYPAD initiative. She’s teaching molecular imaging at the pregraduate and postgraduate level in national and international courses.

**TRACK 1**  
Consensus on Imaging for Early Diagnosis of AD

**TRACK 3**  
Consensus on Research Priorities
Dr. Oskar Hansson gained his PhD in neurobiology in 2001 and his M.D. in 2005. He became senior consultant in neurology in 2012 at Skåne University Hospital, Sweden, and full professor of neurology in 2017 at Lund University, Sweden. His landmark study on cerebrospinal fluid biomarkers for Alzheimer’s disease from 2006 (Hansson et al, The Lancet Neurology, 2016) has been instrumental for the implementation of these biomarkers in the clinical work-up of Alzheimer’s disease in Sweden and internationally. His work on biomarkers has led to over 220 original, peer-reviewed publications. Eight years ago, he started the prospective and longitudinal Swedish BioFINDER study (www.biofinder.se), where the research team focuses on the development of optimized diagnostic algorithms for early diagnosis, and also studies the consequences of different brain pathologies on cognitive, neurologic and psychiatric symptoms in healthy individuals and patients with dementia and parkinsonian disorders.

Karl Herholz is Professor in Clinical Neuroscience at the University of Manchester, UK. He has been leading clinical neuroscience research at the Wolfson Molecular Imaging Centre with particular research interest in PET for early diagnosis and prevention of dementia and imaging of gliomas. Before joining Manchester University he worked as a clinical neurologist and professor of neurology at University Hospital and the Max-Planck Institute for Neurological Research in Cologne, Germany. He has served in leading roles in international multicentre PET studies, including the EU-funded Networks on Diagnostic Molecular Imaging (DiMI), Imaging of Neuroinflammation in Neurodegenerative Diseases (INMIND) and the European Medical Information Framework on Alzheimer’s Disease (EMIF-AD, IMI/FP7). He is also PI on a partnership grant for the MR-PET imaging network of the Dementia Platform UK and was a member of the Medical Research Council Neuroscience and Mental Health Board.
Brian Hutton is Professor of Medical Physics in Nuclear Medicine and Molecular Imaging Science at the Institute of Nuclear Medicine, University College London (UCL). He has worked in Nuclear Medicine since 1975, originally based in teaching hospitals of the University of Sydney. From 2004-17 he directed a research group at UCL with emphasis on SPECT system design, reconstruction in emission tomography and image processing to enable quantification in multi-modality imaging. He has published more than 250 papers in peer reviewed journals and conference proceedings and 17 book chapters. He is also one of the developers of the IAEA Distance Assisted Training Programme for Nuclear Medicine Professionals and continues to assist with its coordination. He was co-recipient of the 2014 IEEE Marie Sklodowska-Curie Award in recognition of his role in development of maximum likelihood reconstruction leading to its widespread and effective use in healthcare.

Clifford R. Jack Jr., M.D., is engaged in brain imaging research in cognitive aging and Alzheimer’s disease and related disorders. Dr. Jack’s research group employs imaging to study the biology of brain aging and cognitive impairment. They also develop image-processing algorithms for quantitatively measuring the information obtained from brain imaging. They employ a variety of brain imaging modalities including anatomic MRI, MR spectroscopy, functional connectivity MR, diffusion MRI, FDG PET, amyloid PET, and tau PET. Dr. Jack’s group serves as the MR center for several large multi-site observational and interventional studies including ADNI and A4. He has received the Potamkin Prize from the American Academy of Neurology, ISMRM Gold Medal, MetLife Foundation Award, RSNA Outstanding Researcher Award, and is a member of the Association of American Physicians and the American Academy of Medicine (formerly Institute of Medicine).
Susan carried out her doctoral and postdoctoral work on memory in aging and dementia in the Helen Wills Neuroscience Institute at the University of California, Berkeley. She is currently Associate Research Neuroscientist at UC Berkeley and in Molecular Biophysics and Integrated Bioimaging at the Lawrence Berkeley National Laboratory. She studies trajectories of cognitive and biomarker change in normal aging and dementia.

She is a PET Core investigator for the Alzheimer’s Disease Neuroimaging Initiative and specializes in amyloid and tau PET imaging throughout the course of disease. She is PI of the PET Cores for the ADNI-Late Life Depression study and for the DOD-ADNI study of aging and imaging biomarkers in Vietnam War Veterans. She serves on the Scientific Program Committee for the Alzheimer’s Association International Conference and on the Editorial Board for the journal Neurology. She received the Christopher Clark Award at Human Amyloid Imaging in 2018.

Prof. Adriaan A. Lammertsma, PhD, has been active in PET research since 1979, when he joined the MRC Cyclotron Unit, Hammersmith Hospital in London. Apart from a sabbatical year at UCLA, Los Angeles, he stayed in London until 1996, when he moved to the VU University Medical Center in Amsterdam. Over the years his research focus has been the development and application of tracer kinetic models for quantitative PET studies with applications in neurology, cardiology and oncology. In addition, he was one of the first to recognise the value of PET in both drug development and precision medicine. He is the 2012 recipient of the Kuhl-Lassen Award from the Society of Nuclear Medicine and the 2015 recipient of the ESMI Award from the European Society of Molecular Imaging. Adriaan Lammertsma is co-author of nearly 500 peer reviewed papers.
Ian Law, Professor, Chief Physician, Ph.D, DMSc., is chairman of the Neuroimaging Committee, European Association of Nuclear Medicine (EANM), Member of the “PET Response Assessment in Neurooncology (RANO) working group” under the European Association of Nuclear Medicine (EANM), European Association of Neurooncology (EANO), and Society of Neurooncology (SNO). Member of the Danish Neurooncology group (DNOG). Primary research interests are clinical implementation of PET/CT and PET/MRI with focus on dementia, neurooncology, and Parkinsons disease. Basic research is performed in cerebral blood flow.

Satoshi Minoshima, M.D., Ph.D. is Professor and Chair of the Department of Radiology and Imaging Sciences at the University of Utah, Salt Lake City, UT, U.S.A. His scientific contributions in the field of Neuroscience include the discovery of very early sign of Alzheimer’s disease in the posterior cingulate cortex and worldwide dissemination of diagnostic statistical mapping technology (3D-SSP / Neurostat). He has published numerous peer-reviewed articles, book chapters, review articles, proceedings, and abstracts and given educational lectures extensively. He currently serves as the President of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the chair of the SNMMI Value Initiative. He was the chair of the SNMMI Scientific Program Committee and the President of the SNMMI Brain Imaging Council and the Chair of the Molecular Imaging Committee for the Radiological Society of North America (RSNA).
21 Silvia MORBELLI  
Genoa, Italy

Silvia Morbelli (MD, PhD) is an Associate Professor of Nuclear Medicine at the University of Genoa. She works as Nuclear Medicine physician at San Martino University Hospital since 2007. She obtained a PhD in Applied Neurosciences in 2010. She has made contributions related to the use of neuroimaging tools as diagnostic and prognostic biomarkers in the earliest and preclinical stages of Neurodegenerative Dementia and Parkinsonian Syndromes. She is especially interested in the use of Molecular Imaging to disclose networks underlying different clinical phenotypes as well as brain reserve in Alzheimer’s and Lewy Body Diseases. She is since 2015 member of the Neuroimaging Committee of the European Association of Nuclear Medicine.

TRACK 2 Consensus on Molecular Imaging for Differential Dementia Diagnosis

22 Flavio NOBILI  
Genoa, Italy

Flavio Nobili is Associate Professor of Neurology at the University of Genoa (I), Dept of Neuroscience. He leads the dementia management team at the IRCCS Ospedale Policlinico San Martino in Genoa. Member of the European Alzheimer Disease Consortium steering committee, past member of the EANM Neurimaging Committee, he is involved in the European DLB Consortium. He is leading the neurology study group of the Italian Association of Nuclear Medicine. Principal investigator in pharma clinical trials in AD and DLB for more than 10 years. He has received research support to study biomarkers in MCI and AD from the European Commission (FP 5; FP 7; Innovative Medicine Initiative; JPND). He is actively involved in management of dementia patients and in reporting of brain molecular imaging exams. He has guided the intersocietal group of panelists from EANM and the EAN to deliver the 2018 recommendations for the use of FDG-PET in dementia. Author or co-author of 282 peer-reviewed publications.

TRACK 1 Controversy: In Favour
23  Agneta NORDBERG
Stockholm, Sweden

Dr Agneta Nordberg obtained her MD and PhD at Uppsala University, Sweden. She is Professor in Clinical Neuroscience at Karolinska Institutet and Senior Consultant, Theme Aging, Karolinska University Hospital, Stockholm. Member of ENCP executive committee 2004-2007, Member of Nobel Assembly 2010-2015 and has obtained several prizes and rewards. Dr Nordberg has been pioneering in the development of amyloid imaging and molecular imaging using multi-tracer PET concept for in vivo pathological studies in patients. She is leading international forefront translational research with focus on understanding underlying pathophysiological processes in brain for Alzheimer’s disease and related disorders and development of early diagnostic biomarkers and new treatment strategies. Dr Nordberg has published over 450 scientific original articles and reviews. She has supervised over 25 PhD students and 24 international post docs. Dr Nordberg has PI for more than 15 clinical trials.

TRACK 3  Clinical Use of “Freely Accessible” Amyloid Markers – The Example of Sweden

TRACK 5  Standards for In-Vitro Validation of PET Tracers in Neurodegeneration

24  Rik OSSENKOPPELE
Amsterdam, Netherlands

Rik Ossenkoppele obtained his PhD (“Alzheimer PEThology”) in 2013 at the Alzheimercenter of the Amsterdam University Medical Center, the Netherlands. He is currently an assistant professor at the Amsterdam University Medical Center and the University of Lund, Sweden. His research group utilizes various neuroimaging techniques (PET: Tau, Aβ, glucose metabolism; MRI: brain atrophy and functional connectivity) to study the Alzheimer’s disease spectrum, with a specific focus on disease heterogeneity and brain resilience. He was awarded the de Leon Prize in Neuroimaging (AAIC, 2017), the Young Investigator award (Human Amyloid Imaging meeting, 2016) and the Alzheimer’s Association Award for Excellence in Research on Alzheimer’s Disease and Related Disorders (2014). He has authored 68 publications and is an associate editor (Neuroimaging section) for Alzheimer’s Research & Therapy.

TRACK 2  Controversy: Amyloid PET-First
Professor Wim Oyen is nuclear medicine physician at the Department of Radiology and Nuclear Medicine of Rijnstate Hospital, Arnhem, The Netherlands and full Professor of Diagnostic Imaging and Radiotherapy at Humanitas University in Milan, Italy. From 2015-2018, he was full Professor of Nuclear Medicine and Molecular Imaging at The Institute of Cancer Research and Head of the Department of Nuclear Medicine of The Royal Marsden Hospital, London, UK. Before working in the UK, he was a nuclear medicine physician and full Professor of Nuclear Medicine at the Radboud University Medical Centre Nijmegen, The Netherlands, serving as Head of the Department of Nuclear Medicine, Member of the Board of the Medical Staff and Director of the Research Institute for Oncology of RadboudUMC. Professor Oyen’s main research interests are molecular imaging in oncology and infectious diseases and radionuclide therapy of cancer. He is the (co-)author of more than 650 original science and review articles in international peer-reviewed journals. He is currently actively involved in the European Association of Nuclear Medicine (Board Member, past-Congress Chair and as of 2019 EANM President) and the International Cancer Imaging Society (President 2017/2018). Professor Oyen is a member of the several Editorial Boards, including the European Journal of Nuclear Medicine and Molecular Imaging and the Journal of Nuclear Medicine.

Prof. Daniela Perani, MD, Neurologist and Radiologist, Full Professor of Neuroscience, San Raffaele University, Milan; Head of the Unit „In vivo Human Molecular and Structural Neuroimaging“ Division of Neuroscience, San Raffaele Scientific Institute, Milan; Coordinator of Diagnostic Neuroimaging at Nuclear Medicine Unit, San Raffaele Hospital, Milan. She is member of the International Societies and Coordinator of several National and International Research Projects in Neurology and Neuroscience. She is the designated responsible of Nuclear Medicine Neurology in the Italian Association of Nuclear Medicine (AIMN). Her researches deal with in vivo molecular imaging studies of neurological diseases, in particular neurodegenerative dementias, and with cognitive neuroscience. She is author of more than 260 full papers.
Dr. Rabinovici is the Edward Fein and Pearl Landrith Distinguished Professor in the University of California San Francisco (UCSF) Department of Neurology. He received his Bachelor’s degree from Stanford University and MD from Northwestern University Medical School. He completed an internship in internal medicine at Stanford University, neurology residency (and chief residency) at UCSF and a behavioral neurology fellowship at the UCSF Memory and Aging Center (MAC).

Dr. Rabinovici’s research investigates how structural, functional and molecular brain imaging techniques can be used to improve diagnostic accuracy in dementia and to study the biology of neurodegenerative diseases, with the goal of accelerating treatment development. He leads the MAC PET imaging program and is principal investigator of Imaging Dementia: Evidence for Amyloid Scanning (IDEAS), a U.S.-wide study to assess the clinical utility of amyloid PET in 18,500 patients with MCI/dementia of uncertain etiology. He is co-PI and PET Core Director of the multi-site Longitudinal Evaluation of Early-Onset Alzheimer’s Disease Study (LEADS).

Prof. Dr. Philip Scheltens studied at the VU University Amsterdam, gaining his MD in 1984, and PhD (Magnetic Resonance Imaging in Alzheimer’s disease) in 1993. Since 2000 he is Professor of Cognitive Neurology and Director of the Alzheimer Center Amsterdam. His main interests are AD, FTD, MRI, PET imaging and fluid biomarkers. He is active in the field of biomarkers and clinical trials and has been the national PI for many studies, including phase 1-3 multicenter clinical trials. He founded and directs the Alzheimer Center since 2000, from which over 55 PhD theses have appeared since then. In 2013, he co-founded the Dutch national plan against dementia and serves as vice-chair of the board since then. He has authored over 850 peer reviewed publications (H-factor is 103). In 2011, he was elected as member of the Royal Dutch Academy of Arts and Sciences (KNAW) and serves as Secretary General since 2015. In 2016 he was awarded the European Grand Prix for Alzheimer’s Research.

**TRACK 2**
Unmet Clinical Needs and Contribution of PET in Frontotemporal Lobar Degeneration

**TRACK 3**
Ongoing Studies to Provide Answers – AMYPAD and Other European Initiatives
PANELLISTS

29 Elsmarieke VAN DE GIESSEN
Amsterdam, Netherlands

2008
Medical Degree
2012
PhD Degree (cum laude) - Imaging of the dopamine and serotonin system in obesity, Academic Medical Center, Amsterdam (Netherlands)
2012-2014
Post-doctoral research fellow, Imaging of the dopamine system in schizophrenia and substance abuse, Columbia University Medical Center, New York State Psychiatric Institute, New York (USA)
2014 - present
Resident in Radiology and Nuclear Medicine, Academic Medical Center, Amsterdam
2014 - present
Research fellow, Imaging of the dopamine and glutamate system in treatment-resistant schizophrenia, Academic Medical Center, Amsterdam
2015 - present
Member of EANM Neuroimaging Committee

SCIENTIFIC FOCUS
Neurotransmitter imaging (PET, SPECT, MRI), Psychiatric disorders, Parkinsonisms

CLINICAL FOCUS
Parkinsonisms, Dementia

30 Victor VILLEMAGNE
Heidelberg, Australia

A/Prof Villemagne graduated Cum Laude from the National University of Buenos Aires in 1983. He continued his post-graduate studies at The Johns Hopkins Medical Institutions, NIDA, NIH, and at the University of Pittsburgh.
A/Prof Villemagne has authored several book chapters and more than 260 original publications on PET research in leading international peer-reviewed journals. Among other honours, he has received the JAAME Fellowship from Japan (2007), the de Leon Prize in Neuroimaging by the Alzheimer’s Association of America (Boston, USA, 07/2013), the Christopher Clark Award for the Continuing Advancement in the Field of Human Amyloid Imaging, Miami (USA, 01/2014), and the Kuhl-Lassen Award by the Society of Nuclear Medicine (USA, 6/2018).
Since 2016, he has been recognized as one of The World’s Most Influential Scientific Minds by Thomson Reuters (based on his citations being in the top 1% in the world in the field of Neuroscience).
Henrik Zetterberg is a Professor of Neurochemistry at the University of Gothenburg, Sweden, and University College London, UK, and a Clinical Chemist at the Sahlgrenska University Hospital in Gothenburg. He is Head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg, and his main research focus and clinical interest is fluid biomarkers for central nervous system diseases, Alzheimer’s disease in particular. He has published more than 900 papers and has received numerous awards.
VENUE ADDRESS
Novotel Cannes Montfleury
25 avenue Beauséjour
06400 Cannes, France
Tel: +33 4 936 886 86

REGISTRATION DESK OPENINGS HOURS
Thursday, January 31 07:30 - 18:00
Friday, February 1 08:00 - 18:00
Saturday, February 2 08:00 - 13:00

CME CREDITS
The EANM Focus 2: The International Conference on “Molecular Imaging of Dementia - The Future is here”, Cannes, France, 31/01/2019-02/02/2019 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 15 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

CERTIFICATE OF ATTENDANCE
A Certificate of Attendance will be available in your personal vEANM Area after the meeting. Only attendees who fill out the evaluation sheet handed out during the meeting will receive the certificate.
CONFERENCE DINNER
The conference dinner is going to take place on Friday, February 1, 2019 at 20:00 at the Beefhouse in Cannes. At 19:30 there will be a bus transfer from the Novotel Cannes Montfleury directly to the restaurant. Starting from 22:30 until 24:00 there will be a shuttle service every approx. 15 minutes back to the hotel.
Location: Beefhouse, 2 Rue Félix Faure, 06400 Cannes

FOOD & BEVERAGES
During the conference, coffee breaks will be provided to all participants. On Thursday night and Saturday noon, during the Welcome Reception and the Farewell Drink, complimentary finger food and drinks will be served.
On Friday night, EANM invites all participants to join the complimentary Conference Dinner (please refer to “Conference Dinner” above).

MEDIA
By attending the event, each participant acknowledges and agrees to grant EANM the right at the Focus Meeting to record, film, photograph or capture the likeness of such participant and its representatives in any media now available and in the future developed, and to use, copy, modify, distribute, broadcast or otherwise disseminate at any time and on a global basis such media, without any further approval from or payment to such participant or any of its representatives.

NAME BADGES
The name badges must be worn at all times during the conference as we are in a hotel together with other guests. Persons without a name badge will be asked to leave the conference rooms.

RECORDING OF SESSIONS
The meeting will be recorded and important parts will be made available online at the EANM/ESMIT eLearning Platform (https://elearning.eanm.org) after the meeting once the production is finalized.
We kindly thank the following companies for their sponsorship engagement:

Platinum Sponsors

SIEMENS Healthineers

Gold Sponsors

Biogen
Cereau Technologies
Life Molecular Imaging
Lilly
Annual Congress of the European Association of Nuclear Medicine

October 12 – 16, 2019
Barcelona, Spain

eanm19.eanm.org